Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.45 |
| ▸ | CASR | P41180 | 2/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5057825 | 0.88 | CYP3A4 (0.37) | NPC1MAPTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL5052977 | 0.87 | GAA (0.41) | KDM4EHSD17B10L3MBTL1FFAR1ALDH1A1 | |
| SCHEMBL5057849 | 0.87 | FOLH1 (0.45) | RAB9AKDM4ENPC1MAPTL3MBTL1 | |
| SCHEMBL5133548 | 0.87 | MAPT (0.39) | RAB9ANPC1MAPTHSD17B10ALDH1A1 | |
| SCHEMBL5054382 | 0.87 | ADRB2 (0.39) | CASRRAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL5053067 | 0.85 | POLB (0.43) | FNTAFNTBPGGT1BITGB3ITGA2B | |
| SCHEMBL7047224 | 0.84 | FFAR1 (0.42) | AKR1C3AKR1C2RAB9AKDM4EMAPT | |
| SCHEMBL5054341 | 0.84 | MTNR1B (0.44) | CASRRAB9ANPC1MEN1KMT2A | |
| SCHEMBL5054407 | 0.84 | FFAR1 (0.38) | KDM4ESMN1; SMN2FFAR1ALDH1A1 | |
| SCHEMBL7053867 | 0.83 | L3MBTL1 (0.48) | RAB9ANPC1MAPTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1066297-B1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2002-10-23 | — | — | EP | claimed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002509934-A | — | — | 2002-04-02 | — | — | JP | claimed |
| EP-1066297-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-10 | — | — | EP | claimed |
| US-6121252-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME INHIBITORS TO TREAT GLUTAMATE ABNORMALITIES AND PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-09-19 | — | — | US | claimed |
| WO-1999050272-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-07 | — | — | WO | claimed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| EP-1066297-B1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARM INC (US) | 2002-10-23 | — | — | EP | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1066297-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999050272-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | AKR1C3 2627/4885CASR 3773/4885MEP1B 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.